Pulmonary Involvement in Patients With Fabry Disease
The objective of this study is to investigate whether Agalsidase alpha, a drug commonly prescribed in patients with Fabry disease, is associated with improvement of the pulmonary involvement. According to the Global Initiative for Obstructive Lung Disease (GOLD), the surrogate markers for obstructive lung diseases are a decrease in both forced expiratory volume in one second (FEV1) and FEV1/FVC ratio, whereas FVC is the forced vital capacity. However, the measurement of these lung function parameters is indicated as yearly follow-up examinations with or without the treatment of Agalsidase alpha in patients with Fabry disease.
|Study Design:||Observational Model: Cohort
Time Perspective: Retrospective
|Official Title:||Impact of the Treatment With Agalsidase Alpha on Lung Function and on Pulmonary Involvement in Patients With Fabry Disease. A Multicenter, Retrospective Observational Study|
- Lung function measurements [ Time Frame: From first consultation until present ] [ Designated as safety issue: No ]Retrospective analysis of yearly measured lung function parameters to investigate on the lung function changes in patients with Fabry disease
|Study Start Date:||July 2012|
|Study Completion Date:||May 2014|
|Primary Completion Date:||May 2014 (Final data collection date for primary outcome measure)|
Other: Lung function measurement
Pulmonary function tests und DLCO measurements are performed yearly in relation with yearly follow up examinations in the Department of Internal Medicine from the University Hospital of Zurich. We will retrospectively collect the results of the pulmonary functions test (spirometry).
Please refer to this study by its ClinicalTrials.gov identifier: NCT01632111
|University Hospital Zurich, Division of Internal Medicine|
|Principal Investigator:||Daniel Franzen, MD||University Hospital Zurich, Division of Internal Medicine|